Rubicon Filter
This article was originally published in The Gray Sheet
Executive Summary
Embolic protection device indication for use in saphenous vein grafts will be sought using data from a conventional, single-device U.S. study, expected to begin early in 2005, Rubicon Medical says. Initial plans for a joint, randomized RULE-SVG trial with Boston Scientific's Taxus Liberté paclitaxel-eluting stent have been scrapped to ensure "fewer delays and complexities" following FDA feedback, the firm explains (1"The Gray Sheet" Aug. 23, 2004, In Brief). Separately, Rubicon has finalized a license for SurModics' hydrophilic coating to enhance filter deliverability...
You may also be interested in...
Peripheral DES trial
Rubicon Medical and Boston Scientific expect to launch the RULE-SVG trial of Boston Scientific's Taxus Liberté paclitaxel-eluting stent used in conjunction with Rubicon's Rubicon Filter embolic protection device for the treatment of diseased saphenous vein grafts by year-end, pending IDE approval. The trial will randomize Taxus Liberté patients to treatment with the Rubicon Filter or Boston Scientific's EPI Filterwire, and be used to support regulatory filings for Taxus Liberté and Rubicon Filter in the U.S. (1"The Gray Sheet" March 1, 2004, In Brief)...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.